We found that serum levels of MIP-3α and cystatin A in pretreatment patients with NPC were higher than those in healthy controls; the majority of patients had decreased levels of MIP-3α and cystatin A during the therapy. The gene discussed is CSTA; the disease is nasopharyngeal carcinoma.